tradingkey.logo


tradingkey.logo


Zoetis Inc

ZTS
116.630USD
-0.080-0.07%
āļ›āļīāļ” 03/26, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
58.31BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
19.35P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Zoetis Inc āļšāļĢāļīāļĐāļąāļ—

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

āļ‚āđ‰āļ­āļĄāļđāļĨ Zoetis Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ZTS
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Zoetis Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļFeb 01, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Peck (Kristin C)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™13800
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Feb 01
āļ—āļĩāđˆāļ­āļĒāļđāđˆ10 Sylvan Way
āđ€āļĄāļ·āļ­āļ‡PARSIPPANY
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX NASDAQ Basic NYSE
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ07054
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ19738227000
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.zoetis.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ZTS
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļFeb 01, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Peck (Kristin C)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Zoetis Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
105.88K
+10.27%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
-7.15%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
16.26K
+6.17%
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+0.39%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.71K
+9.15%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Independent Director
Independent Director
3.92K
+28.11%
Mr. Jamie Brannan
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
3.71K
+30.18%
Mr. Keith Sarbaugh
Mr. Keith Sarbaugh
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
2.34K
+12.94%
Mr. Nicholas (Nick) Ashton
Mr. Nicholas (Nick) Ashton
Executive Vice President, President - Global Manufacturing and Supply
Executive Vice President, President - Global Manufacturing and Supply
1.82K
+39.96%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
105.88K
+10.27%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
-7.15%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
16.26K
+6.17%
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+0.39%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.71K
+9.15%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
āļ­āļ·āđˆāļ™ āđ†
380.00M
15.83%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
1.32B
55.08%
Other emerging markets
228.00M
9.50%
Other Developed
164.00M
6.83%
Brazil
100.00M
4.17%
Australia
87.00M
3.62%
āļ­āļ·āđˆāļ™ āđ†
499.00M
20.79%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
āļ­āļ·āđˆāļ™ āđ†
380.00M
15.83%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 19 āļ.āļž.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 19 āļ.āļž.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
11.27%
BlackRock Institutional Trust Company, N.A.
5.63%
State Street Investment Management (US)
4.69%
State Farm Insurance Companies
4.00%
Wellington Management Company, LLP
2.70%
āļ­āļ·āđˆāļ™ āđ†
71.71%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
11.27%
BlackRock Institutional Trust Company, N.A.
5.63%
State Street Investment Management (US)
4.69%
State Farm Insurance Companies
4.00%
Wellington Management Company, LLP
2.70%
āļ­āļ·āđˆāļ™ āđ†
71.71%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
51.20%
Investment Advisor/Hedge Fund
33.30%
Research Firm
4.13%
Insurance Company
4.08%
Pension Fund
2.94%
Bank and Trust
2.62%
Hedge Fund
1.45%
Sovereign Wealth Fund
1.45%
Individual Investor
0.09%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 21 āļĄ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 21 āļĄ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2026Q4
2795
428.61M
99.51%
--
2025Q4
3335
436.13M
98.96%
-14.08M
2025Q3
3275
435.62M
98.29%
-1.39M
2025Q2
3277
434.35M
98.00%
-1.58M
2025Q1
3284
432.42M
97.12%
-4.21M
2024Q4
3199
430.60M
96.14%
-9.58M
2024Q3
3090
434.14M
95.81%
-13.19M
2024Q2
3062
437.75M
95.94%
-9.33M
2024Q1
3060
439.45M
96.16%
-2.63M
2023Q4
3074
438.13M
95.43%
-2.08M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
The Vanguard Group, Inc.
47.78M
10.84%
+5.68M
+13.48%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
22.80M
5.17%
+144.71K
+0.64%
Sep 30, 2025
State Street Investment Management (US)
19.65M
4.46%
-89.97K
-0.46%
Sep 30, 2025
State Farm Insurance Companies
16.87M
3.83%
+21.40K
+0.13%
Sep 30, 2025
Wellington Management Company, LLP
8.54M
1.94%
-348.26K
-3.92%
Sep 30, 2025
Geode Capital Management, L.L.C.
11.14M
2.53%
+57.14K
+0.52%
Sep 30, 2025
Morgan Stanley Investment Management Ltd. (UK)
7.48M
1.7%
+722.07K
+10.69%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
5.19M
1.18%
+131.36K
+2.60%
Jun 30, 2025
Polen Capital Management, LLC
7.52M
1.71%
-904.12K
-10.74%
Sep 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
ProShares Pet Care ETF
9.4%
VanEck Pharmaceutical ETF
9.02%
VanEck Agribusiness ETF
7.81%
iShares U.S. Pharmaceuticals ETF
4.26%
Honeytree US Equity ETF
3.86%
First Trust NASDAQ Pharmaceuticals ETF
3.58%
Polen Capital Global Growth ETF
3.35%
State Street SPDR S&P Pharmaceuticals ETF
2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
2.47%
Themes US R&D Champions ETF
1.96%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ProShares Pet Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™9.4%
VanEck Pharmaceutical ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™9.02%
VanEck Agribusiness ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™7.81%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™4.26%
Honeytree US Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.86%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.58%
Polen Capital Global Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.35%
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.47%
Themes US R&D Champions ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.96%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 2.56B USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
Feb 05, 2026
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Jun 02, 2026 going ex on Apr 20, 2026
Apr 20, 2026
Jun 02, 2026
Apr 20, 2026
Dec 11, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Mar 03, 2026 going ex on Jan 20, 2026
Jan 20, 2026
Mar 03, 2026
Jan 20, 2026
Oct 09, 2025
ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025
Oct 31, 2025
Dec 02, 2025
Oct 31, 2025
May 21, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025
Jul 18, 2025
Sep 03, 2025
Jul 18, 2025
Feb 06, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025
Apr 21, 2025
Jun 03, 2025
Apr 21, 2025
Dec 12, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
Jan 21, 2025
Mar 04, 2025
Jan 21, 2025
Oct 10, 2024
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
Oct 31, 2024
Dec 03, 2024
Oct 31, 2024
May 22, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
Jul 18, 2024
Sep 04, 2024
Jul 18, 2024
Feb 06, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
Apr 19, 2024
Jun 04, 2024
Apr 18, 2024
Dec 07, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Mar 01, 2024
Jan 18, 2024
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™